Drug Profile
Research programme: small molecule anti-cancer therapeutics - NeoPhore
Latest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator NeoPhore
- Developer NeoPhore; University of Torino
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA repair inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer